FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      
           
This page is updated frequently with new Roti-related patent applications. Subscribe to the Roti RSS feed to automatically get the update: related Roti RSS feeds. RSS updates for this page: Roti RSS RSS


Date/App# patent app List of recent Roti-related patents
04/23/15
20150112359
 Electrical stimulation of the carotid artery patent thumbnailnew patent Electrical stimulation of the carotid artery
In order to treat hypertension, an implantable receiving device is connected to implantable leads which are adapted to deliver electrical energy to the carotid body or bodies of the patient. The receiving device is arranged to receive electoral energy from an external generator.
Bioinduction Limited
04/23/15
20150111947
 Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage patent thumbnailnew patent Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) mrna expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases map4k4 mrna expression in an endothelial cell and additional therapeutic agents..
University Of Massachusetts
04/23/15
20150111872
 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailnew patent Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .
04/23/15
20150111824
 Pharmaceutical formulations comprising incretin mimetic peptide and aprotic polar solvent patent thumbnailnew patent Pharmaceutical formulations comprising incretin mimetic peptide and aprotic polar solvent
The present disclosure is directed to stable pharmaceutical formulations and uses thereof.. .
Astrazeneca Pharmaceuticals Lp
04/23/15
20150110895
 Methods of treating necrotic enteritis patent thumbnailnew patent Methods of treating necrotic enteritis
Methods of treating necrotic enteritis are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.. .
Liveleaf, Inc.
04/16/15
20150104462
 Use of semaphorin-4d binding molecules for treatment of atherosclerosis patent thumbnailUse of semaphorin-4d binding molecules for treatment of atherosclerosis
Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4d (sema4d) or to its high affinity plexin-b1 receptor.. .
Vaccinex, Inc.
04/09/15
20150099919
 Control of magnetic rotors to treat therapeutic targets patent thumbnailControl of magnetic rotors to treat therapeutic targets
A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources.
Pulse Therapeutics, Inc.
04/02/15
20150094465
 N-alkoxyamide conjugates as imaging agents patent thumbnailN-alkoxyamide conjugates as imaging agents
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
04/02/15
20150094384
 Methods for predicting and treating necrotizing enterocolitis in neonates patent thumbnailMethods for predicting and treating necrotizing enterocolitis in neonates
Embodiments are presented herein that provide early prediction of the development of necrotizing enterocolitis by a preterm infant through analysis of the high frequency component of heart rate variability, optionally with analysis of respiration rate. Methods of treatment following prediction area also reported..
The Penn State Research Foundation
03/26/15
20150086627
 Dosage forms of halofuginone and methods of use patent thumbnailDosage forms of halofuginone and methods of use
Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.. .
Halo Therapeutics, Llc.
03/26/15
20150086596

Organophosphates for treating afflictions of the skin


Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of demodex mites in affected skin areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method.
03/26/15
20150086529

Therapeutic burn gel


Therapeutic radiation burn gel is an invention that promotes the healing of radiated skin. It works by softening the layers of necrotic tissue which form (in the skin) post radiation.
03/26/15
20150086515

Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle


Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-rgd4c fusion polypeptides for tumor treatment, thereby reducing side effects of tnf. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered mscs after administration into a recipient animal.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150080686

Atherosclerotic plaque detection


An apparatus detects atherosclerotic plaques. The apparatus includes an electronic processing device that determines a level of fluorescence sensed by a sensor at a second infrared wavelength in response to exposure of at least part of an artery to radiation at a first infrared wavelength and determines a fluorescence indicator using the level of fluorescence.
Baker Idi Heart & Diabetes Institute Holdings Limited
03/19/15
20150080320

Multi-target modulation for treating fibrosis and inflammatory conditions


The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer..
Aadigen, Llc
03/19/15
20150079055

Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease


An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the h-1, h-2, lewisb and lewisy antigens and derivatives thereof (e.g., a sialylated form of lewis a, lewis x, lewis b, lewis y; h-1, h-2, lewis a, lewis x, lewis b or lewis y)..
Instituto Nacional De Ciencias Medicas Y Nutricion
03/19/15
20150078997

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
03/12/15
20150073400

Tissue treatment


There is provided in accordance with an exemplary embodiment of the invention a method and/or a device of treating tissue near a first lumen comprising inserting an energy emission element into a second lumen and delivering energy in an amount sufficient to cause one or more spaced apart areas of tissue damage at preselected locations in tissue near the first lumen. There is also provided a method and/or a device for treating a carotid artery wall, for example, to reduce signal conduction.
Cardiosonic Ltd.
03/12/15
20150072962

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis


5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virgini Commonwealth University
03/05/15
20150065947

Cell-seeded compositions and methods useful for treating bone regions


Compositions and methods for treating diseased or damaged bone, preferably ischemic and/or necrotic bone, include the use of a combination of endothelial progenitor cells and mesenchymal stem cells, desirably also in conjunction with a collagenous extracellular matrix tissue. Methods for preparation of such compositions are also described..
Muffin Incorporated
02/26/15
20150057216

Angiotensins for treatment of fibrosis


The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided..
Tarix Pharmaceuticals Ltd.
02/26/15
20150056217

Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4 associated disorders


The present invention relates to the use of a tlr9 agonist and/or a tlr4 antagonist and/or a nod2 agonist for treatment or prevention of disorders involving tlr4 activation, such as systemic sepsis and necrotizing enterocolitis.. .
University Of Pittsburgh - Of The Commonwealth System Of Highter Education
02/26/15
20150056133

Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease


The present invention relates to cx3cr1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain cx3cr1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described.
02/19/15
20150051215

Pi3k inhibitors for treating fibrotic diseases


The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (ipf).. .
Glaxosmithkline Intellectual Property (no.2) Limited
02/19/15
20150048821

Atherosclerosis characterization using a multi-contrast mri sequence


The present invention relates to imaging and characterizing atherosclerotic lesions. The invention utilizes a low-flip-angle gradient echo-based mri acquisition technique combined with specialized magnetization preparative schemes (i.e.
Cedars-sinai Medical Center
02/12/15
20150045675

Percutaneous methods and devices for carotid body ablation


Methods and percutaneous devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via percutaneous carotid body ablation.. .
02/12/15
20150045403

Pharmaceutical cream compositions and methods of use


Embodiments relating to cream formulations as well as oxymetazoline creams and methods for treating rosacea and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith; other inflammatory conditions of the skin including, but not limited to, keratosis pilaris, lupus miliaris dissemniatus faciei, eczema, dermatitis, such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, statis dermatitis, neurodermatitis, lichen simplex chronicus, xerosis and xerotic dermatitis, dyshidrosis and dyshidrotic dermatitis, asteototic dermatitis or other conditions characterized by sensitive skin or a disturbance of the epidermal barrier; disorders characterized by rough, dry, cracked or fissured skin, disorders characterized by hyperkeratotic skin such as keratodermas and ichthyosisis and ichthyosiform dermatoses; disorders of hair follicles and sebaceous glands, such as acne, perioral dermatitis, and pseudofolliculitis barbae; disorders of sweat glands, such as miliaria, including, but not limited to, miliaria crystallina, miliaria rubra, miliaria profunda, miliaria pustulosa; sunburn, chronic actinic damage, poikiloderma, radiation dermatitis, actinic purpura (“solar purpura”); other inflammatory dermatoses, reactions and conditions of the skin, including, but not limited to, psoriasis, drug eruptions, erythema multiforme, erythema nodosum, and granuloma annulare; diseases and conditions characterized by bleeding or bruising such as petechiae, ecchymosis, purpura and the like including any accumulation of blood in the skin due to vascular extravasation, irrespective of size or cause, bleeding or bruising due to any skin injury which may include any trauma including surgical or procedural trauma; infection, inflammatory dermatoses or inflammation due to any cause using such creams are described herein.. .
Allergan, Inc.
02/05/15
20150038405

Pharmaceutical composition for preventing or treating arteriosclerosis


The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of seq id no: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis..
Eyegene, Inc.
02/05/15
20150037399

Novel use of pipoxolan and its pharmaceutical composition


The present disclosure concerns the novel use of pipoxolan and its pharmaceutical composition. Pipoxolan is useful therapeutic drugs for pathological conditions caused by vascular smooth muscle cell proliferation and migration to relieve a body appeared vascular injury, cerebrovascular ischemia, intimal hyperplasia, atherosclerotic stenosis, cerebral ischemia, and stroke..
China Medical University
01/29/15
20150032197

Carotid stent assembly and methods for treatment via body lumens


A stent assembly adapted to carotid arterial placement that includes a self-expanding support element comprising metal struts constructed to be positioned in a body lumen and expanded from a retracted state to an expanded state, and a knitted cover disposed over an exterior of the support element and along an entire length thereof, wherein the knitted cover comprises a single polymer fiber having a diameter of at least 40 nanometers to 30 microns, wherein the self-expanding support element and knitted cover together have apertures sized 20 microns to smaller than 100 microns in diameter to block larger debris when the stent assembly is placed in a carotid artery and expanded to the expanded state. Methods of stenting a carotid artery by applying the stent assembly to the carotid artery of a patient in need of treatment and expanding the stent assembly in situ are disclosed..
Inspiremd, Ltd
01/22/15
20150025616

Method and treating a carotid artery


One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery..
Silk Road Medical, Inc.
01/15/15
20150018942

Method of implanting an aortic stent


A method of implanting an aortic stent comprising steps of: putting a main tube on a metal guide wire; moving the main tube along the metal guide wire to the descending aorta, the main tube is constrained by a first cover, and first and second tube bifurcations are branched from the main section; removing the first cover; inserting a second and third metal guide wire through the first tube bifurcation into the ascending aorta and branchiocephalic artery respectively; a first and a second tube branch moving into the ascending aorta and the branchiocephalic artery respectively; inserting a fourth and fifth metal guide wire through the first tube bifurcation into the ascending aorta and branchiocephalic artery respectively; a third and a fourth tube branch moving into left common carotid artery and the left subclavian artery respectively; removing a second cover constraining said tube branches.. .
01/15/15
20150017151

Pharmaceutical formulations of xanthine or xanthine derivatives, and their use


The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.. .
Imprimis Pharmaceuticals, Inc.
01/08/15
20150010615

Supercritical guggul extracts and uses thereof


The subject invention pertains to supercritical carbon dioxide extracts of commiphora mukul resin (guggul), which can be modified or not modified by some ethanol addition; methods for their production; and methods of use, such as inhibiting hmg-coa reductase, inhibiting transformation of pre-adipocytes to adipocytes, inhibiting triglyceride storage, promoting insulin sensitivity in adipocytes, treatment of disorders (for example, hypercholesterolemia, hyperlipidemia, hyperglycemia, obesity, metabolic syndrome, cardiovascular disease, atherosclerotic heart disease, autoimmune disorder, insulin resistance, leptin resistance, arthritis, cell proliferation disorder, such as cancer and atherosclerosis; damaged skin, sores, cuts, rashes, bruises, dryness, burns, sunburn, radiation burn, and infection), and regulating or suppressing appetite.. .
Flavex Naturextrakte Gmbh
01/01/15
20150005645

Detection of a leading stroke risk indicator


Embodiments of a system and method for detecting a leading stroke risk indicator using low-cost, non-contact visual computing methods are generally described herein. In some embodiments, a video camera is arranged to capture a video of a face of a subject to be evaluated for having a stroke risk indicator.
12/25/14
20140377365

Sustained-release formulation of rotigotine


Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation.
Map Pharmaceuticals, Inc.
12/25/14
20140377189

Pulmonary administration of rotigotine


Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a stable solution formulation of rotigotine that is suitable for administration via oral inhalation.
Map Pharmaceuticals, Inc.
12/25/14
20140376687

Systems for characterizing atherosclerotic plaque and methods of using same


The present technology relates generally to systems for characterizing atherosclerotic plaque, such as a spectral ct system, and methods of using same.. .
University Of Washington Through Its Center For Commercialization
12/18/14
20140371653

Methods and systems for establishing retrograde carotid arterial blood flow


Interventional procedures on the carotid arteries are performed through a transcervical access while retrograde blood flow is established from the internal carotid artery to a venous or external location. A system for use in accessing and treating a carotid artery includes an arterial access device, a shunt fluidly connected to the arterial access device, and a flow control assembly coupled to the shunt and adapted to regulate blood flow through the shunt between at least a first blood flow state and at least a second blood flow state.
Silk Road Medical, Inc.
12/18/14
20140371594

Estimation and display for vector doppler imaging using plane wave transmissions


Vector doppler imaging (vdi) improves on conventional color doppler imaging (cdi) by giving speed and direction of blood flow at each pixel of a display generated by a computing system. Multiple angles of plane wave transmissions (pwt) via an ultrasound transducer conveniently give projected doppler measurements over a wide field of view, providing enough angular diversity to identify velocity vectors in a short time window while capturing transitory flow dynamics.
Verasonics, Inc.
12/18/14
20140371593

Ultrasound diagnostic device and controlling ultrasound diagnostic device


An ultrasound diagnostic device for measuring a carotid artery wall property includes a transmission-reception processor, a transverse cross-sectional image generator, a transverse cross-sectional image selector, and a relative angle calculator. The transmission-reception processor performs transmission and reception processing of ultrasound with respect to the carotid artery.
Konica Minolta, Inc.
12/18/14
20140371089

Method for diganosing atherosclerotic plaques by measurement of cd36


The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of cd36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.3063

3824

2 - 1 - 75